You are here

Inflammation and cancer-related fatigue: Mechanisms, contributing factors, and treatment implications

Julienne E. Bower, Donald M. Lamkin

Brain, Behavior, and Immunity, Volume 30, Supplement, 15 March 2013, Pages S48–S57

Editors' comments: Dr. Ricardo Caponero 

Fatigue is one of the most common and distressing side effects of cancer and its treatment, and may persist for years after treatment completion in otherwise healthy survivors.
Twenty-two percent of the survivors had severe persistent fatigue in the year after cancer treatment. Fatigue and cognitive behavioral factors predicted persistent fatigue in the year after cancer treatment. Diagnosis or cancer treatment did not predict persistent fatigue. The implication is that cognitive behavioral therapy for postcancer fatigue, aimed at the fatigue-perpetuating factors, could be offered from two months after successful cancer treatment.
This review article examines the current state of the evidence linking inflammation and cancer-related fatigue, and considers neural mechanisms and risk factors.